Industry committee  My understanding is that, as Mr. Garneau mentioned, it would reinsert schedule 1 into Canada's access to medicines regime, along with potentially another amendment, which I suppose we'll discuss later. But it's not clear to me how the other schedules, the country schedules, would

Industry committee  Bill C-393 proposed, as Mr. Marc Garneau said, to remove schedule 1, which is a list of drugs that was contained in CAMR, the drugs that were eligible for manufacture and export under the regime. It also contained three lists of countries--so schedules 2 to 4. The countries tha

Industry committee  That's right. It would be—

Industry committee  —one schedule of countries only, removed--

Industry committee  That is correct.

Industry committee  That is correct, and the amendment, as I understand it, would refer to clauses 2 to 4.

Industry committee  Clause 2 as it was put forward in Bill C-393 would have deleted the reference to schedule 1 and would have expanded the scope of eligible products for export under Canada's access to medicines regime to any drug as defined under section 2 of the Food and Drugs Act. That would hav

Industry committee  I will just add that the intent.... When CAMR was first developed, when this legislation was first put in place, we were one of the first countries to do such legislation. We were developing the legislation without much precedent, so what was paramount was the interest in making

Industry committee  I was only going to add that I think it is because clause 2 of Bill C-393 states, “Section 21.02 of the Act is replaced by the following”, and there are two definitions after that. One is for “authorization” and one is for “pharmaceutical product”. So the understanding was that w

Industry committee  I'll answer that question by listing the definitions that are currently in CAMR. There are definitions for: “authorization”, “General Council”, “General Council Decision”, “patented product”, “pharmaceutical product”, “TRIPS Agreement”, “TRIPS Council”, and “WTO”. Bill C-393 woul

Industry committee  Not alone, no. Clause 9, on section 21.09, of Bill C-393 and clause 10, on section 21.12, of Bill C-393 would also delete the renewal and that duration of the export, so--

Industry committee  Yes.

Industry committee  Yes, in the sense that.... Section 21.03 of the Patent Act currently refers to schedule 1, the list of drugs, and the process for adding to those drugs on the recommendation of the Minister of Industry and the Minister of Health. Bill C-393 would delete not only schedule 1, but t

Industry committee  If I understand what Liberal amendment 5 does, it restores Bill C-393's schedule of countries; it restores schedule 1 of the Patent Act, which currently lists the drugs that are eligible for export under CAMR, and it references Bill C-393's list of countries as schedule 2. That w

Industry committee  The simple answer is no. If you revert to the pharmaceutical product definition that is in the Patent Act currently, there is no reference to any ability to add to that list on the recommendation of the Minister of Industry and the Minister of Health. That ability is found in sec